Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Change in Acquisitions & Divestments (2023 - 2024)

Lyra Therapeutics (LYRA) has disclosed Change in Acquisitions & Divestments for 2 consecutive years, with $28.1 million as the latest value for Q4 2024.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 41.62% to $28.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was $130.6 million, a 17.77% increase, with the full-year FY2024 number at $130.6 million, up 17.77% from a year prior.
  • Change in Acquisitions & Divestments was $28.1 million for Q4 2024 at Lyra Therapeutics, up from $21.0 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $51.0 million in Q2 2024 to a low of $9.8 million in Q1 2023.